Natural history and mid-term prognosis of severe tricuspid regurgitation: A cohort study.

Objectives

The objective of this study was to characterize a population of patients with severe tricuspid regurgitation (TR) evaluated at a tertiary care center, assess mid-term clinical outcomes, and identify prognostic factors.

Background

The impact of TR on morbidity and mortality is increasingly recognized. Clinical characteristics and long-term outcomes of patients suffering from TR remain unclear.

Methods

This is a retrospective observational single-center study from a tertiary care hospital including patients with echocardiographic diagnosis of severe TR between January 2017 and December 2018. We used the Kaplan-Meier method to estimate survival for up to 4 years. After excluding patients with tricuspid valve (TV) intervention and surgery during follow-up, a multivariate analysis was performed to assess predictors of 2-year mortality using the Cox regression model.

Results

A total of 278 patients (mean age 74.9 ± 13.7 years, 47.8% female) with severe TR were included in the study. The majority (83.1%;

Conclusion

Our study shows the high burden of morbidity and the dismal survival of patients with severe TR. It also highlights the extent of the therapeutic need, since the vast majority of patients were left untreated. Additionally, CIED RV lead-associated TR was prevalent suggesting a need for more attention in clinical routine and research.

Informations de copyright

Copyright © 2023 Samim, Praz, Cochard, Brugger, Ruberti, Bartkowiak, Corpataux, Reineke, Pilgrim, Windecker, Wenaweser and Wild.

Déclaration de conflit d'intérêts

DS received a training grant from Edwards Lifesciences. FP was compensated for travel expenses by Abbott Vascular, Edwards Lifesciences, and Polares Medical. TP received research grants to the institution from Biotronik, Boston Scientific, and Edwards Lifesciences; consutancy/speaker fees from Biotronik, Boston Scientific, Medtronic, Abbott, and HighLife SAS. SW reports research and educational grants from Abbott, Amgen, Astra Zeneca, BMS, Bayer, Biotronik, Boston Scientific, Cardinal Health, CardioValve, CSL Behring, Daiichi Sankyo, Edwards Lifesciences, Guerbet, InfraRedx, Johnson&Johnson, Medicure, Medtronic, Novartis, Polares, OrPha Suisse, Pfizer, Regeneron, Sanofi-Aventis, Sinomed, SSS International, Terumo, and V-Wave. MW received speaker Honoria from Edwards Lifesciences. PW reports Proctoring/Consulting Fees from Edwards Lifesciences and Medtronic; Honoraria Daiichi Sankyo. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The reviewer PD declared a past co-authorship with the authors MW and FP to the handling editor.